Suchen
Radiopharm Theranostics Ltd
RADXZur Watchlist hinzufügen
4.370USD
+0.100+2.34%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Radiopharm Theranostics Ltd Unternehmen
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Radiopharm Theranostics Ltd Informationen
BörsenkürzelRADX
Name des UnternehmensRadiopharm Theranostics Ltd
IPO-datumNov 25, 2021
CEOCanevari (Riccardo)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
Geschäftsjahresende- -
AddresseLevel 3, 62 Lygon Street
StadtMELBOURNE
BörseNASDAQ OMX - NASDAQ BASIC
LandAustralia
Postleitzahl3053
Telefon61398245254
Websitehttps://radiopharmtheranostics.com/
BörsenkürzelRADX
IPO-datumNov 25, 2021
CEOCanevari (Riccardo)
Führungskräfte von Radiopharm Theranostics Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Riccardo Canevari
Mr. Riccardo Canevari
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Hester Larkin
Ms. Hester Larkin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phillip Hains
Mr. Phillip Hains
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Bruce Goodwin
Mr. Bruce Goodwin
Non-Executive Director
Non-Executive Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Riccardo Canevari
Mr. Riccardo Canevari
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Hester Larkin
Ms. Hester Larkin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Radiopharm Theranostics Ltd?
Die fünf größten Anteilseigner von Radiopharm Theranostics Ltd sind: Mr. Riccardo Canevari
Wie viele Institutionen halten Anteile an Radiopharm Theranostics Ltd (RADX)?
Mit Stand vom 2026Q1 halten 11 Institutionen Anteile an Radiopharm Theranostics Ltd, mit einem Gesamtmarktwert von etwa 51.39M, was 3.30% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 50862187.00 gestiegen.